GI CANCERS

According to additional analyses from the phase III RESORCE trial published in the<em> Journal of Hepatology,&nbsp;s</em>econd-line regorafenib continued to show antitumor activity regardless of prior dose or time to progression on frontline sorafenib (Nexavar) for patients with unresectable advanced hepatocellular carcinoma.

Carlos Becerra, MD, recently shared the treatment considerations and decisions he makes when treating patients with metastatic colorectal cancer and hepatocellular carcinoma. Becerra, a medical oncologist at Texas Oncology, Baylor Charles A. Sammons Cancer Center, explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses results of the CELESTIAL trial. The results were clinically and statistically significant, Abou-Alfa notes.&nbsp;

Overall survival was extended in patients with&nbsp;hepatocellular carcinoma and elevated baseline alpha-fetoprotein (AFP) who received second-line treatment with ramucirumab (Cyramza) versus placebo,&nbsp;according to findings from the phase III REACH-2 trial.

The US Department of Defense has selected Sanjeevani Arora, PhD, as the recipient of the Peer Reviewed Cancer Research Program Career Development award and grant for fiscal year 2017.&nbsp;The grant will be used to fund clinical efforts benefiting both military and civilian patients.

According to early results of an ongoing early-phase study presented at the 2018 Society of Interventional Radiology Annual Scientific Meeting, image-guided injections of talimogene laherparepvec immunotherapy (T-VEC, Imylgic) were deemed tolerable in patients with advanced-stage liver metastases.

Internationally renowned expert, Johanna C. Bendell, MD, has been promoted to chief development officer at Sarah Cannon. Her title responsibilities include developing and expanding physician, site, and Pharma relationships across the Sarah Cannon Network, thereby expanding the organization&rsquo;s efforts to bring more qualitative treatment options to its patients.